These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 29146274)

  • 21. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Ahn C; Tsai FS; Lai HM; Gandhi K; Amin H; Frishman WH; Kalapatapu K; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):37-40. PubMed ID: 19966176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the Wearable Cardioverter-Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry.
    El-Battrawy I; Koepsel K; Tenbrink D; Kovacs B; Dreher TC; Blockhaus C; Gotzmann M; Klein N; Kuntz T; Shin DI; Lapp H; Rosenkaimer S; Abumayyaleh M; Hamdani N; Saguner AM; Kowitz J; Erath JW; Duru F; Mügge A; Akin I; Aweimer A; Beiert T
    J Am Heart Assoc; 2023 Sep; 12(18):e030615. PubMed ID: 37681569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
    Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
    Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of outcome of Indian patients who meet MADIT II (Multicenter Automatic Defibrillator Implantation Trial) criteria for implantable cardioverter defibrillator implantation: is it appropriate for Indian patients?
    Yadav R; Chandra A; Yadav G; Naik N
    Indian Heart J; 2020; 72(3):172-178. PubMed ID: 32768016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy.
    Kühlkamp V;
    J Am Coll Cardiol; 2002 Mar; 39(5):790-7. PubMed ID: 11869843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study.
    Revuelta-López E; Núñez J; Gastelurrutia P; Cediel G; Januzzi JL; Ibrahim NE; Emdin M; VanKimmenade R; Pascual-Figal D; Núñez E; Gommans F; Lupón J; Bayés-Genís A
    ESC Heart Fail; 2020 Apr; 7(2):559-566. PubMed ID: 32045114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction.
    Haugaa KH; Grenne BL; Eek CH; Ersbøll M; Valeur N; Svendsen JH; Florian A; Sjøli B; Brunvand H; Køber L; Voigt JU; Desmet W; Smiseth OA; Edvardsen T
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):841-50. PubMed ID: 23850251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of rapid-rate non-sustained ventricular tachycardia in the occurrence of appropriate implantable cardioverter-defibrillator therapy.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    J Interv Card Electrophysiol; 2020 Apr; 57(3):473-480. PubMed ID: 31073687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
    Packer M
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e007430. PubMed ID: 31159583
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
    Wachter R; Shah SJ; Cowie MR; Szecsödy P; Shi V; Ibram G; Zhao Z; Gong J; Klebs S; Pieske B
    ESC Heart Fail; 2020 Jun; 7(3):856-864. PubMed ID: 32297449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.
    Packer M
    JACC Heart Fail; 2019 Oct; 7(10):902-906. PubMed ID: 31521684
    [No Abstract]   [Full Text] [Related]  

  • 35. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
    Kadish A; Dyer A; Daubert JP; Quigg R; Estes NA; Anderson KP; Calkins H; Hoch D; Goldberger J; Shalaby A; Sanders WE; Schaechter A; Levine JH;
    N Engl J Med; 2004 May; 350(21):2151-8. PubMed ID: 15152060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).
    AlJaroudi WA; Refaat MM; Habib RH; Al-Shaar L; Singh M; Gutmann R; Bloom HL; Dudley SC; Ellinor PT; Saba SF; Shalaby AA; Weiss R; McNamara DM; Halder I; London B;
    Am J Cardiol; 2015 Apr; 115(7):924-31. PubMed ID: 25682436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
    Young JB; Abraham WT; Smith AL; Leon AR; Lieberman R; Wilkoff B; Canby RC; Schroeder JS; Liem LB; Hall S; Wheelan K;
    JAMA; 2003 May; 289(20):2685-94. PubMed ID: 12771115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?".
    Zecchin M; Merlo M; Pivetta A; Barbati G; Lutman C; Gregori D; Serdoz LV; Bardari S; Magnani S; Di Lenarda A; Proclemer A; Sinagra G
    Am J Cardiol; 2012 Mar; 109(5):729-35. PubMed ID: 22176998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.